Kalaris Therapeutics, Inc. (KLRS)
Data as of , from SEC Form 4 filings.
See up to 3 months of KLRS. The 7-day demo opens the 1M and 3M ranges and puts KLRS on your watchlist.
Start 7-day demoLatest KLRS insider trades
Srinivas AkkarajuOpen-market purchase$1.18M- Brett R. Hagen - OfficerOpen-market sale$13K
About Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. is an SEC registrant, filing under CIK 0001754068, classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
KLRS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 3 | 248,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
KLRS insider transactions (Form 4)
3538 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Amy O'Leary Vandekop - Officer | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Laurie Keating - Director | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
 Liisa Ann Bayko - Officer | Grant or award | Stock Option (Right to Buy) | 220,000 | $0.00 | - | |
 Morana Jovan-Embiricos | Grant or award | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
| Napoleone Ferrara | Grant or award | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
 David Hallal | Grant or award | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
| Srinivas Akkaraju | Grant or award | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
| Michael Dybbs | Grant or award | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
| Anthony P. Adamis | Grant or award | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
| Leone D. Patterson | Grant or award | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
| Srinivas Akkaraju | Open-market purchase | Common Stock | 244,300 | $4.83 | $1.18M | |
| Srinivas Akkaraju | Other | Common Stock | 14,937 | $0.00 | - | |
| Srinivas Akkaraju | Other | Common Stock | 66,906 | $0.00 | - | |
| Srinivas Akkaraju | Other | Common Stock | 4,471 | $0.00 | - | |
| Brett R. Hagen - Officer | Open-market sale | Common Stock | 1,915 | $6.72 | $13K | |
| Brett R. Hagen - Officer | Grant or award | Stock Option (Right to Buy) | 60,800 | $0.00 | - | |
| Andrew Oxtoby - Officer | Grant or award | Stock Option (Right to Buy) | 222,000 | $0.00 | - | |
| Matthew Gall - Officer | Grant or award | Stock Option (Right to Buy) | 95,000 | $0.00 | - | |
| Matthew Feinsod - Officer | Grant or award | Stock Option (Right to Buy) | 135,000 | $0.00 | - | |
| Srinivas Akkaraju | Open-market purchase | Common Stock | 479,847 | $10.42 | $5.00M | |
| Matthew Gall - Officer | Grant or award | Stock Option (Right to Buy) | 235,000 | $0.00 | - | |
| Samir Chandrakant Patel | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Anthony P. Adamis | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Srinivas Akkaraju | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Leone D. Patterson | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Edward Miller - Officer | Gift | Common Stock | 57,549 | $0.00 | - | |
| Edward Miller - Officer | Gift | Common Stock | 57,549 | $0.00 | - | |
 Diana Brainard - Officer | Open-market sale | Common Stock | 8,706 | $0.55 | $5K | |
| Brett R. Hagen - Officer | Open-market sale | Common Stock | 554 | $0.55 | $304 | |
| Edward Miller - Officer | Open-market sale | Common Stock | 432 | $0.55 | $237 | |
 Vikas Sinha - Officer | Open-market sale | Common Stock | 3,186 | $0.55 | $2K | |
| Diana Brainard - Officer | Open-market sale | Common Stock | 10,609 | $0.86 | $9K | |
| Brett R. Hagen - Officer | Open-market sale | Common Stock | 1,655 | $0.86 | $1K | |
| Edward Miller - Officer | Open-market sale | Common Stock | 2,272 | $0.86 | $2K | |
| Vikas Sinha - Officer | Open-market sale | Common Stock | 5,136 | $0.86 | $4K |
KLRS insider trading FAQ
What is the latest insider trade for KLRS?
Kalaris Therapeutics, Inc. (KLRS) had 3 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for KLRS runs to 38 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying KLRS stock?
No insider purchases of KLRS were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling KLRS stock?
No insider sales of KLRS were filed in the last 90 days. 20 sales are on record for this company.
Where can I see KLRS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects KLRS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Amy O'Leary Vandekop view on EDGAR
- - Laurie Keating view on EDGAR
- - Liisa Ann Bayko view on EDGAR
- - Morana Jovan-Embiricos view on EDGAR
- - Napoleone Ferrara view on EDGAR
- - David Hallal view on EDGAR
- - Srinivas Akkaraju view on EDGAR
- - Michael Dybbs view on EDGAR
- - Anthony P. Adamis view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where KLRS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow KLRS with a 7-day demo
- KLRS on your watchlist
- Every KLRS Form 4 filing on record
- Up to 3 months of KLRS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
